A carregar...

Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform

Metastatic breast cancer is developed in about 20–30% of newly diagnosed early stage breast cancer patients despite treatments. Herein, we report a novel nanoparticle platform with intrinsic anti-metastatic properties for the targeted delivery of Polo-like kinase 1 siRNA (siPLK1). We first evaluated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Morry, Jingga, Ngamcherdtrakul, Worapol, Gu, Shenda, Reda, Moataz, Castro, David J., Sangvanich, Thanapon, Gray, Joe W., Yantasee, Wassana
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445934/
https://ncbi.nlm.nih.gov/pubmed/28138033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0644
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!